Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | THRB | P10828 | 1/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.58 |
| ▸ | CD69 | Q07108 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.48 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.48 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.48 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29013440 | 1.00 | ALDH1A1 (0.61) | ALDH1A1THRBMAPK1CD69SMN1; SMN2 | |
| SCHEMBL29735890 | 1.00 | ALDH1A1 (0.61) | ALDH1A1THRBMAPK1CD69SMN1; SMN2 | |
| SCHEMBL18710872 | 1.00 | ALDH1A1 (0.61) | ALDH1A1THRBMAPK1CD69SMN1; SMN2 | |
| SCHEMBL7152633 | 1.00 | ALDH1A1 (0.61) | ALDH1A1THRBMAPK1CD69SMN1; SMN2 | |
| SCHEMBL5679031 | 1.00 | ALDH1A1 (0.61) | ALDH1A1THRBMAPK1CD69SMN1; SMN2 | |
| SCHEMBL15334201 | 1.00 | ALDH1A1 (0.61) | ALDH1A1THRBMAPK1CD69SMN1; SMN2 | |
| SCHEMBL317138 | 1.00 | ALDH1A1 (0.61) | ALDH1A1THRBMAPK1CD69SMN1; SMN2 | |
| SCHEMBL22410446 | 1.00 | ALDH1A1 (0.61) | ALDH1A1THRBMAPK1CD69SMN1; SMN2 | |
| SCHEMBL20552181 | 1.00 | ALDH1A1 (0.61) | ALDH1A1THRBMAPK1CD69SMN1; SMN2 | |
| SCHEMBL1521416 | 1.00 | ALDH1A1 (0.61) | ALDH1A1THRBMAPK1CD69SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170095493-A1 | NOVEL TLR4 INHIBITORS FOR THE TREATMENT OF HUMAN INFECTIOUS AND INFLAMMATORY DISORDERS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2017-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170095493-A1 | NOVEL TLR4 INHIBITORS FOR THE TREATMENT OF HUMAN INFECTIOUS AND INFLAMMATORY DISORDERS | TLR4, TLR3, TLR1 | ALDH1A1 4563/4885THRB 490/4885MAPK1 149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.